AesRx, a US-based biopharmaceutical company backed by MedImmune Ventures (wholly-owned corporate venturing fund within the AstraZeneca Group, founded in 2002 for investing in emerging healthcare), has raised $1.36m convertible debt out of a $1.53m offering, according to a 9 May regulatory filing. AesRX is also backed by Fidelity Biosciences, a venture capital division of mututal…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
